SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Tuesday March 31 2015

This event will examine the drug excipients market, from the historical events that have defined the sector to the debates going on at the moment to predictions about the demands that will drive it in the future.

How did the DEG tragedies of the last century shape the regulatory landscape?
Does the sector need GMP rules?
How will the dosage forms of the future guide innovation in the excipients industry?

Conference programme webinars:
EI15-WRBM1-WC-SL-IPT-March-2015-Overview of the specialty excipients market for OSDF pharmaceuticals

Overview of the specialty excipients market for OSDF pharmaceuticals - by William Reed Business Media

Gareth Macdonald - In-Pharmatechnologist.com, Nikola Matic - Kline & Company

Consumption patterns in the 4 key global markets (Europe, US, India, China) Key market drivers and...

EI15-Capsugel-WC-SL-IPT-March-2015-Quality Risk Management for excipients

Quality Risk Management for excipients - by Capsugel

Kaat Bracquiné - Capsugel

Capsugel is the first hard capsule manufacturer to receive the EXCiPACT™ certification. The certification provides...

EI15-Dow-WC-SL-IPT-March-2015-Dow AFFINISOL™ polymers for Solubility Enhancement

Dow AFFINISOL™ polymers for Solubility Enhancement - by Dow Pharma & Food Solutions

Kevin O’Donnell - Dow Pharma & Food Solutions, William "Trey" Porter III - Dow Pharma & Food Solutions

Dow has developed the AFFINISOL™ line of excipients to enable solubility enhancement.Hypromellose acetate succinate (HPMCAS)...

Wednesday March 27th 2014

It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.
But, while this characteristic - bioavailability - has been the focus of lab scientists, clinical researchers and process developers’ efforts for many years, finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms.
Similarly, biopharmaceutical firms hoping to develop oral delivery alternatives for injectable biologics will also need to work out how to ensure that their products are bioavailable, safe and effective.
Our virtual event will bring together expert regulators, academics and the drug industry scientists to define the challenges and share the latest research breakthroughs to help you make the decisions that will let you overcome your Bioavailability Challenge.

Conference programme webinars:
BAC14-WB-SL-IPT-March-2014-Role of excipients in design of solid amorphous drug dispersions for delivery of poorly water-soluble drugs

Role of excipients in design of solid amorphous drug dispersions for delivery of poorly water-soluble drugs - by Ashland

Divya Tewari - Ashland

Most new drug candidates suffer from poor water- solubility leading to rate limiting dissolution, slow...

BAC14-WB-SL-IPT-March-2014-Dow AFFINISOL™ polymers for Solubility Enhancement

Dow AFFINISOL™ polymers for Solubility Enhancement - by Dow Pharma & Food Solutions

Kevin O’Donnell - The Dow Chemical Company, William "Trey" Porter III - The Dow Chemical Company

Dow’s AFFINISOL™ line of excipients include AFFINISOL™ HMPCAS for spray drying applications and AFFINISOL™ HPMC...

BAC14-BASF-WB-SL-IPT-March-2014-How glass-forming polymers improve bioavailability / Enhanced oral bioavailability with Soluplus® – case study

How glass-forming polymers improve bioavailability / Enhanced oral bioavailability with Soluplus® – case study - by BASF SE

Felicitas Guth - BASF, Heiko Alexander Schiffter - BASF

How glass-forming polymers improve bioavailabilityPolymers are essential components of oral solid dosage forms and used...

BAC14-IPT-WRBM#1-Bioavailability market dynamics

Bioavailability market dynamics - by William Reed Business Media

Dan Stanton - In-Pharmatechnologist.com / Outsourcing-Pharma.com, Deepika Chopda - Frost & Sullivan

How healthy is demand for bioavailability enhancement services? Is the growth of the generics sector...

BAC14-IPT-WRBM#2-A brief history of bioavailability

A brief history of bioavailability - by William Reed Business Media

Damien Bove - Yorkshire Biotec, Gareth Macdonald - In-Pharmatechnologist.com / Outsourcing-pharma.com

Tablets have been around for almost 200 years. In this presentation we trace the history...